1-3 of 3
Riadh Lobbardi
Close
Sort by
Journal Articles

CFT8634, a Clinical Stage BRD9 Bi DAC™ Degrader, Is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic When Combined with Pomalidomide

Laura L Poling, David Cocozziello, Minsheng He, Eunju Hurh, Riadh Lobbardi, Katrina L Jackson, Stewart L Fisher, Roy M Pollock
Journal: Blood
Blood (2023) 142 (Supplement 1): 6594.
https://doi.org/10.1182/blood-2023-174555
Published: 2023
Journal Articles

CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents

Samantha Perino, R. Jason Kirby, Roman Agafonov, Prasoon Chaturvedi, Scott Eron, Andrew Good, Ashley Hart, Minsheng He, Riadh Lobbardi, Andrew J Phillips, David Proia, James Henderson, Michael Thomeius, Christopher Nasveschuk, Stewart L Fisher, Roy Macfarlane Pollock
Journal: Blood
Blood (2022) 140 (Supplement 1): 11575.
https://doi.org/10.1182/blood-2022-166541
Published: 2022
Journal Articles

Thymocyte Selection-Associated High-Mobility Group Box Protein (TOX) Induces Genomic Instability in T-Cell Acute Lymphoblastic Leukemia

Riadh Lobbardi, PhD, Jordan Pinder, PhD, Barbara Martinez-Pastor, PhD, Jessica S Blackburn, PhD, Nouran Abdelfattah, Deborah Toiber, PhD, Manon De Waard, John M. Asara, PhD, Raul Mostoslavsky, MDPhD, Graham Dellaire, PhD, David M. Langenau, PhD
Journal: Blood
Blood (2014) 124 (21): 475.
https://doi.org/10.1182/blood.V124.21.475.475
Published: 2014